Nicotinic acetylcholine receptors expressed in the ventralposterolateral thalamic nucleus play an important role in anti-allodynic effects
- PMID: 20136830
- PMCID: PMC2848924
- DOI: 10.1111/j.1476-5381.2009.00613.x
Nicotinic acetylcholine receptors expressed in the ventralposterolateral thalamic nucleus play an important role in anti-allodynic effects
Abstract
Background and purpose: Much interest is currently being focused on the anti-nociceptive effects mediated by nicotinic acetylcholine (nACh) receptors, including their location and mechanism of action. The purpose of this study was to elucidate these issues using 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine (5IA), a nACh receptor agonist, and [(125)I]5IA.
Experimental approach: We partially ligated the sciatic nerve of Sprague-Dawley rat to induce neuropathic pain [Seltzer's partial sciatic nerve ligation (PSL) model]. We then examined the changes in nACh receptor density in the CNS using [(125)I]5IA autoradiography and the involvement of nACh receptors in anti-nociceptive effects in the region where changes occurred.
Key results: Autoradiographic studies showed that the accumulation of [(125)I]5IA and the number of nACh receptors in the thalamus of PSL rats were increased about twofold compared with those in the sham-operated rats. No change was observed in other brain regions. Rats injected in the ventral posterolateral thalamic nucleus (VPL) with 5IA demonstrated a significant and dose-dependent anti-allodynic effect and this effect was completely antagonized by mecamylamine, injected with 5IA, into the VPL. The blockade of nACh receptors in the VPL by mecamylamine decreased by 70% the anti-allodynic effect of 5IA, given i.c.v. Moreover, mecamylamine given intra-VPL by itself, induced significant hyperalgesia.
Conclusions and implications: Our findings suggest that the nACh receptors expressed in the VPL play an important role in the anti-allodynic effects produced by exogenous and endogenous agonists.
Figures





Similar articles
-
In vivo relationship between thalamic nicotinic acetylcholine receptor occupancy rates and antiallodynic effects in a rat model of neuropathic pain: persistent agonist binding inhibits the expression of antiallodynic effects.Synapse. 2011 Jan;65(1):77-83. doi: 10.1002/syn.20819. Synapse. 2011. PMID: 20506320
-
Potentiation of analgesic efficacy but not side effects: co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats.Biochem Pharmacol. 2011 Oct 15;82(8):967-76. doi: 10.1016/j.bcp.2011.05.007. Epub 2011 May 17. Biochem Pharmacol. 2011. PMID: 21620806
-
Evaluation of radioiodinated 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine as a ligand for SPECT investigations of brain nicotinic acetylcholine receptors.Ann Nucl Med. 2002 May;16(3):189-200. doi: 10.1007/BF02996300. Ann Nucl Med. 2002. PMID: 12126044
-
The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594.J Physiol Paris. 1998 Jun-Aug;92(3-4):221-4. doi: 10.1016/s0928-4257(98)80014-4. J Physiol Paris. 1998. PMID: 9789812 Review.
-
A-85380: a pharmacological probe for the preclinical and clinical investigation of the alphabeta neuronal nicotinic acetylcholine receptor.CNS Drug Rev. 2006 Summer;12(2):100-12. doi: 10.1111/j.1527-3458.2006.00100.x. CNS Drug Rev. 2006. PMID: 16958984 Free PMC article. Review.
Cited by
-
Exploring Cholinergic Compounds for Peripheral Neuropathic Pain Management: A Comprehensive Scoping Review of Rodent Model Studies.Pharmaceuticals (Basel). 2023 Sep 27;16(10):1363. doi: 10.3390/ph16101363. Pharmaceuticals (Basel). 2023. PMID: 37895835 Free PMC article.
-
Influence of neuropathic pain on nicotinic acetylcholine receptor plasticity and behavioral responses to nicotine in rats.Pain. 2018 Nov;159(11):2179-2191. doi: 10.1097/j.pain.0000000000001318. Pain. 2018. PMID: 29939964 Free PMC article.
-
Neuronal nicotinic receptors as analgesic targets: it's a winding road.Biochem Pharmacol. 2013 Oct 15;86(8):1208-14. doi: 10.1016/j.bcp.2013.08.001. Epub 2013 Aug 12. Biochem Pharmacol. 2013. PMID: 23948066 Free PMC article. Review.
-
Pharmacological characterization of 5-iodo-A-85380, a β2-selective nicotinic receptor agonist, in mice.J Psychopharmacol. 2022 Nov;36(11):1280-1293. doi: 10.1177/02698811221132214. Epub 2022 Nov 2. J Psychopharmacol. 2022. PMID: 36321267 Free PMC article.
-
PET imaging of hypoxia-inducible factor-1-active tumor cells with pretargeted oxygen-dependent degradable streptavidin and a novel 18F-labeled biotin derivative.Mol Imaging Biol. 2011 Oct;13(5):1003-10. doi: 10.1007/s11307-010-0418-6. Mol Imaging Biol. 2011. PMID: 20838908
References
-
- Bannon AW, Decker MW, Curzon P, Buckley MJ, Kim DJ, Radek RJ, et al. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization. J Pharmacol Exp Ther. 1998a;285:787–794. - PubMed
-
- Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly-Roberts D, Puttfarcken PS, et al. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science. 1998b;279:77–81. - PubMed
-
- Bannon AW, Decker MW, Kim DJ, Campbell JE, Arneric SP. ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neuropathy models of neuropathic pain. Brain Res. 1998c;801:158–163. - PubMed
-
- Bitner RS, Nikkel AL, Curzon P, Arneric SP, Bannon AW, Decker MW. Role of the nucleus raphe magnus in antinociception produced by ABT-594: immediate early gene responses possibly linked to neuronal nicotinic acetylcholine receptors on serotonergic neurons. J Neurosci. 1998;18:5426–5432. - PMC - PubMed